Regulator Flags Data Integrity And Manufacturing Lapses At Dadra Facility
Dabur India has come under regulatory scrutiny after the US Food and Drug Administration (FDA) issued an import alert for drugs manufactured at one of the company’s facilities in Dadra and Nagar Haveli.
The action follows an FDA inspection that identified multiple concerns related to data integrity, equipment maintenance, and manufacturing practices at the plant. As a result, products manufactured at the facility may now be detained at US ports without physical examination unless importers can demonstrate that the issues highlighted by the regulator have been adequately addressed.
The development marks a significant regulatory challenge for one of India’s oldest and largest consumer goods companies, which has a growing presence in international healthcare and wellness markets.
FDA Inspection Revealed Serious Compliance Concerns
According to the inspection findings, the US regulator identified lapses in manufacturing controls and documentation practices at the facility.
A Reuters report last month, citing the FDA inspection report, revealed that investigators found instances where critical manufacturing records were allegedly falsified. The report claimed that records had been altered to conceal the use of certain equipment for multiple products, raising concerns about compliance with manufacturing standards.
The inspection also highlighted sanitation issues at the facility. Among the observations, FDA inspectors reportedly found a live bird and bird droppings inside a raw material warehouse located close to packaging materials, triggering additional concerns regarding hygiene and contamination controls.
The findings prompted the regulator to place products manufactured at the facility under an import alert.
What The Import Alert Means
An FDA import alert allows US authorities to detain products entering the country without conducting a physical inspection.
Companies whose products are placed under import alert must provide evidence that corrective measures have been implemented before shipments can be released into the US market.
The mechanism is commonly used by the FDA when it believes a manufacturing facility may not be complying with current Good Manufacturing Practices (cGMP) or other regulatory requirements.
Dabur Says Business Operations Remain Unaffected
Responding to the development, Dabur stated that the FDA’s action will not have any material financial or operational impact on its business.
The company emphasized that products sold in the Indian market are not affected by the order and that the import alert is limited to products manufactured at the specific facility identified by the regulator.
Dabur also said it is actively engaging with the US FDA and has already submitted corrective and preventive action plans aimed at addressing the concerns raised during the inspection.
According to the company, efforts are underway to implement the necessary improvements and close the identified compliance gaps.
Important Market For Ayurvedic And Consumer Health Products
Founded more than 140 years ago, Dabur is among India’s largest consumer healthcare and Ayurvedic products companies.
The company sells a wide range of products in international markets, including over-the-counter healthcare products such as pain relief gels, antifungal creams, cough and cold remedies, and oral care products.
The United States remains an important market for Indian healthcare and wellness brands, making regulatory compliance a critical component of international expansion strategies.
Regulatory Compliance Under Increasing Focus
The latest FDA action highlights the growing scrutiny faced by pharmaceutical and healthcare product manufacturers supplying the US market.
Regulators have increasingly tightened oversight of manufacturing standards, data integrity practices, and quality control systems across global supply chains.
For Dabur, the immediate priority will be resolving the issues identified by the FDA and securing the removal of the import alert to ensure continued access to one of the world’s largest healthcare markets.
